A New Agency for Science Historians?

In his piece on "Historians and Science Policy," J.L. Heilbron makes a timely point with his usual cogency and wit. The science of the twentieth century is distinctive in its scale, its specialization and its close coupling with economic and military concerns. An individual instrument such as the Superconducting Supercollider may cost billions of dollars. The payoffs on research in biotechnology can make or break long-established corporations. Plainly, the mechanisms by which science policy is a

Written byArnold Thackray
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The science of the twentieth century is distinctive in its scale, its specialization and its close coupling with economic and military concerns. An individual instrument such as the Superconducting Supercollider may cost billions of dollars. The payoffs on research in biotechnology can make or break long-established corporations. Plainly, the mechanisms by which science policy is articulated must grow and change along with science itself.

Over the past decade, historians and sociologists of science have been hard at work analyzing the workings of the American scientific community in the twentieth century. That analysis reveals a science more complex and more human than any found in the textbooks. Our modern world of science has 'grown and thrived with the clash of interest groups; with the use of concepts, techniques and theory to define "turf'; with the energizing work of charismatic leaders; with the role of research schools in organizing loyalties and agendas; ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies